Reference number : GC-2017-Q3-00364, amendment number : , agreement type : G, recipient legal name : Willerth, Stephanie (University of Victoria), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Collaborative Research and Development Grants - Project, program name french : Subventions de recherche et développement coopérative - projet, program purpose english : The market for cell culture media and supplements is estimated to be $6 billion per year as reported by Global Industry Analysts Inc. The overall goal of this project is to validate novel protein therapeutics consisting of transcription factors functionalized with a novel intracellular protein delivery technology developed by iProgen Biotech for use as cell culture supplements. This project represents a continuation of a successful collaboration between Dr. Stephanie Willerth, a Canada Research Chair in Biomedical Engineering and Associate Professor of Biomedical Engineering at the University of Victoria, and the biotechnology company - iProgen Biotech. Our previous collaboration validated a novel protein therapeutic called IASCL1 for use as a cell culture supplement that promoted the differentiation of human induced pluripotent stem cells into neurons, which are cells found in the central nervous system. We also have promising preliminary data that IASCL can directly reprogram skin cells called fibroblasts into neuron-like cells. This project will further characterize ability of IASCL1 to reprogram fibroblasts into neurons as well as characterize the effects of other novel transcription factors, including ISOX2, IBRN2, IMYT1L, and INGN2, on the reprogramming process._x000D_
_x000D_, program purpose french : The market for cell culture media and supplements is estimated to be $6 billion per year as reported by Global Industry Analysts Inc. The overall goal of this project is to validate novel protein therapeutics consisting of transcription factors functionalized with a novel intracellular protein delivery technology developed by iProgen Biotech for use as cell culture supplements. This project represents a continuation of a successful collaboration between Dr. Stephanie Willerth, a Canada Research Chair in Biomedical Engineering and Associate Professor of Biomedical Engineering at the University of Victoria, and the biotechnology company - iProgen Biotech. Our previous collaboration validated a novel protein therapeutic called IASCL1 for use as a cell culture supplement that promoted the differentiation of human induced pluripotent stem cells into neurons, which are cells found in the central nervous system. We also have promising preliminary data that IASCL can directly reprogram skin cells called fibroblasts into neuron-like cells. This project will further characterize ability of IASCL1 to reprogram fibroblasts into neurons as well as characterize the effects of other novel transcription factors, including ISOX2, IBRN2, IMYT1L, and INGN2, on the reprogramming process._x000D_
_x000D_, agreement title english : Validation of functionalized transcription factors as a novel cell culture supplements, agreement title french : Validation of functionalized transcription factors as a novel cell culture supplements, agreement number : CRDPJ, agreement value : 100000.0, agreement start date : 2017-12-13, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2019-2020)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2019-2020)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada